期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 28, 期 5, 页码 777-782出版社
WILEY
DOI: 10.1111/jgh.12152
关键词
gastric cancer; meta-analysis; neoadjuvant chemotherapy; randomized controlled trial
资金
- Sixth Affiliated Hospital of Sun Yat-sen University
Background and Aim Although the effect of neoadjuvant chemotherapy in gastric cancer has been extensively studied, the data of survival benefit are still controversial. The purpose of this work was to assess the effectiveness of neoadjuvant chemotherapy followed by surgery in patients with gastric cancer. Methods We searched systematically electronic through the databases of PUBMED, EMBASE, China Biological Medicine, and China National Knowledge Infrastructure Whole Article for studies published from 1975. Two reviewers independently evaluated the relevant reports and searched manually reference from these reports for additional trials. Outcomes assessed by meta-analysis included overall survival rate, progression-free survival rate, R0 resection rate, downstaging effect, postoperative complications, and perioperative mortality. Results Six randomized, controlled trials with 781 patients were included in the meta-analysis. Odds ratio (95% confidence interval; P-value), expressed as neoadjuvant chemotherapy and surgery versus surgery alone, was 1.16 (0.851.58; P=0.36) for overall survival, 1.24 (0.781.96; P=0.36) for R0 resection, 1.25 (0.752.09; P=0.39) for postoperative complications, and 3.60 (0.5922.45; P=0.17) for perioperative mortality. Conclusions Compared with surgery alone, neoadjuvant chemotherapy followed by surgery was not associated with a higher rate of overall survival or complete resection (R0 resection). It does not increase treatment-related morbidity and mortality. This meta-analysis did not demonstrate a survival benefit for the combination of neoadjuvant chemotherapy and surgery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据